IL146025A0 - Improved pharmaceutical formulations comprising at least one hiv protease inhibiting compound - Google Patents

Improved pharmaceutical formulations comprising at least one hiv protease inhibiting compound

Info

Publication number
IL146025A0
IL146025A0 IL14602500A IL14602500A IL146025A0 IL 146025 A0 IL146025 A0 IL 146025A0 IL 14602500 A IL14602500 A IL 14602500A IL 14602500 A IL14602500 A IL 14602500A IL 146025 A0 IL146025 A0 IL 146025A0
Authority
IL
Israel
Prior art keywords
pharmaceutical formulations
hiv protease
inhibiting compound
improved pharmaceutical
protease inhibiting
Prior art date
Application number
IL14602500A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23269615&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146025(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL146025A0 publication Critical patent/IL146025A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14602500A 1999-06-04 2000-05-25 Improved pharmaceutical formulations comprising at least one hiv protease inhibiting compound IL146025A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32582699A 1999-06-04 1999-06-04
PCT/US2000/014342 WO2000074677A2 (en) 1999-06-04 2000-05-25 Improved pharmaceutical formulations

Publications (1)

Publication Number Publication Date
IL146025A0 true IL146025A0 (en) 2002-07-25

Family

ID=23269615

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14602500A IL146025A0 (en) 1999-06-04 2000-05-25 Improved pharmaceutical formulations comprising at least one hiv protease inhibiting compound
IL146025A IL146025A (en) 1999-06-04 2001-10-18 Dissolving drug containing ritonavir and organic solvent containing a mixture of long-chain fatty acids ethanol and water
IL216686A IL216686A (en) 1999-06-04 2011-11-29 Ritonavir-containing drug solution and organic solvent containing a mixture of long fatty acids and water

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL146025A IL146025A (en) 1999-06-04 2001-10-18 Dissolving drug containing ritonavir and organic solvent containing a mixture of long-chain fatty acids ethanol and water
IL216686A IL216686A (en) 1999-06-04 2011-11-29 Ritonavir-containing drug solution and organic solvent containing a mixture of long fatty acids and water

Country Status (33)

Country Link
EP (2) EP1183026B1 (el)
JP (1) JP4753511B2 (el)
KR (1) KR100815412B1 (el)
CN (2) CN100418527C (el)
AR (2) AR032586A1 (el)
AT (2) ATE332132T1 (el)
AU (1) AU778198B2 (el)
BG (1) BG65445B1 (el)
BR (1) BR0007294A (el)
CA (1) CA2371109C (el)
CL (1) CL2008003491A1 (el)
CO (1) CO5160323A1 (el)
CY (2) CY1105237T1 (el)
CZ (1) CZ301308B6 (el)
DE (2) DE60029219T2 (el)
DK (2) DK1183026T3 (el)
ES (2) ES2324549T5 (el)
HK (1) HK1045804A1 (el)
HU (1) HU229501B1 (el)
IL (3) IL146025A0 (el)
MX (1) MXPA01012478A (el)
MY (1) MY127908A (el)
NO (1) NO328968B1 (el)
NZ (1) NZ515016A (el)
PL (1) PL197671B1 (el)
PT (2) PT1733725E (el)
SA (1) SA00210237B1 (el)
SI (2) SI1183026T1 (el)
SK (2) SK287185B6 (el)
TR (1) TR200103488T2 (el)
TW (1) TWI244390B (el)
WO (1) WO2000074677A2 (el)
ZA (1) ZA200108641B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
JP4753511B2 (ja) * 1999-06-04 2011-08-24 アボット・ラボラトリーズ 改良された医薬製剤
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
DE60028754T2 (de) 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
JP4769400B2 (ja) * 2000-01-19 2011-09-07 アボット・ラボラトリーズ 改良された医薬配合物
CA2448438A1 (en) * 2001-05-25 2002-12-05 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
KR20160074018A (ko) * 2005-12-30 2016-06-27 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
AU2015258296B2 (en) * 2006-07-07 2017-08-17 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2013204805C1 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
NO345893B1 (no) * 2006-07-07 2021-09-27 Gilead Sciences Inc Modulatorer av farmakokinetikkegenskaper til terapeutika
AU2015234299B2 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
RS55351B1 (sr) 2007-02-23 2017-03-31 Gilead Sciences Modulatori farmakokinetičkih svojstava lekova
AU2015204378B2 (en) * 2007-02-23 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2013204817B2 (en) * 2007-02-23 2015-05-07 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
SG183059A1 (en) 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
AU2008275744A1 (en) * 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2009088719A1 (en) 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL110752A (en) † 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) † 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
EP0788346B9 (en) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulsified drug delivery systems
DE4431489A1 (de) * 1994-09-03 1996-03-07 Heidelberger Baustofftech Gmbh Schnellhärtende aminosilanvernetzende Silikonmassen
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
CA2238977A1 (en) * 1995-12-13 1997-06-19 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
JP4753511B2 (ja) * 1999-06-04 2011-08-24 アボット・ラボラトリーズ 改良された医薬製剤

Also Published As

Publication number Publication date
CN101361723A (zh) 2009-02-11
BR0007294A (pt) 2002-08-27
DE60029219D1 (de) 2006-08-17
DK1183026T3 (da) 2006-11-06
CZ301308B6 (cs) 2010-01-06
MXPA01012478A (es) 2003-10-14
KR20020011994A (ko) 2002-02-09
SI1733725T2 (sl) 2012-10-30
CN100418527C (zh) 2008-09-17
AR064309A2 (es) 2009-03-25
NO20015670D0 (no) 2001-11-20
DK1733725T4 (da) 2012-09-17
AU778198B2 (en) 2004-11-25
NO328968B1 (no) 2010-06-28
ATE332132T1 (de) 2006-07-15
CN101361723B (zh) 2013-11-06
IL216686A0 (en) 2012-01-31
SK17202001A3 (sk) 2002-03-05
CY1109135T1 (el) 2014-07-02
CZ20014293A3 (cs) 2002-03-13
PT1183026E (pt) 2006-11-30
MY127908A (en) 2006-12-29
EP1183026A2 (en) 2002-03-06
ES2324549T5 (es) 2012-10-31
NO20015670L (no) 2001-11-20
CL2008003491A1 (es) 2009-03-06
DE60042092D1 (de) 2009-06-04
SK287185B6 (sk) 2010-02-08
IL146025A (en) 2012-04-30
CN1353607A (zh) 2002-06-12
TWI244390B (en) 2005-12-01
EP1733725B2 (en) 2012-08-08
DE60029219T2 (de) 2007-06-28
IL216686A (en) 2014-01-30
EP1183026B1 (en) 2006-07-05
ATE429224T1 (de) 2009-05-15
CO5160323A1 (es) 2002-05-30
HU229501B1 (hu) 2014-01-28
PL197671B1 (pl) 2008-04-30
ES2324549T3 (es) 2009-08-10
HUP0201591A3 (en) 2002-10-28
BG65445B1 (bg) 2008-08-29
ZA200108641B (en) 2003-01-20
CY1105237T1 (el) 2010-03-03
PT1733725E (pt) 2009-06-30
CA2371109C (en) 2011-04-26
NZ515016A (en) 2004-02-27
JP4753511B2 (ja) 2011-08-24
DK1733725T3 (da) 2009-08-03
JP2003501386A (ja) 2003-01-14
PL351943A1 (en) 2003-07-14
EP1733725B1 (en) 2009-04-22
CA2371109A1 (en) 2000-12-14
WO2000074677A2 (en) 2000-12-14
SI1733725T1 (sl) 2009-08-31
WO2000074677A3 (en) 2001-02-22
ES2265946T3 (es) 2007-03-01
SI1183026T1 (sl) 2006-10-31
AU5287700A (en) 2000-12-28
HUP0201591A2 (en) 2002-09-28
KR100815412B1 (ko) 2008-03-20
EP1733725A1 (en) 2006-12-20
SK286305B6 (en) 2008-07-07
SA00210237B1 (ar) 2006-11-07
AR032586A1 (es) 2003-11-19
HK1045804A1 (en) 2002-12-13
TR200103488T2 (tr) 2002-04-22
BG106239A (en) 2002-08-30

Similar Documents

Publication Publication Date Title
IL146025A0 (en) Improved pharmaceutical formulations comprising at least one hiv protease inhibiting compound
HUP0202513A2 (en) Betha-carboline pharmaceutical compositions
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
IL147756A (en) Preserved pharmaceutical formulations
IL147778A0 (en) Pharmaceutical compositions containing cyclobenzaprine
AU6219601A (en) Pharmaceutical compositions
HK1044476A1 (en) Medicinal compositions
HUP0201372A3 (en) Pharmaceutical compositions comprising cyclosporin
GB0009584D0 (en) Pharmaceutical compositions
GB9923436D0 (en) Pharmaceutical compositions
EP1166786A4 (en) MEDICAL COMPOSITIONS
AU8576801A (en) Pharmaceutical compositions
GB9904163D0 (en) Pharmaceutical compositions
AU1390002A (en) Pharmaceutical compositions
GB9911017D0 (en) Pharmaceutical compositions
EP1173216A4 (en) PHARMACEUTICAL FORMULATIONS
GB9924992D0 (en) Pharmaceutical aerosol formulations
HUP0302070A3 (en) Pharmaceutical formulations containing ritonavir or other hiv protease inhibiting compounds
GB9904911D0 (en) Pharmaceutical compositions
GB9906126D0 (en) Pharmaceutical formulations
GB9930578D0 (en) Pharmaceutical formulations
GB9902651D0 (en) Pharmaceutical compositions
GB9911826D0 (en) Pharmaceutical formulations
GB9905983D0 (en) Pharmaceutical formulations